Table 2.
Demographic and clinical characteristics of patients with RA harboring Collinsella aerofaciens.
| Variables | Collinsella aerofaciens (OTUs), Median (p25–p75) | p |
|---|---|---|
| Women Men |
113.0 (44.0–345.5) 63.0 (27.5–190.0) |
0.636 |
| Smoking | 0.036 | |
| Non-Smoker, n (%) | 49.0 (19.0–154.0) | |
| Former Smoker, n (%) | 204.0 (60.0–1020.0) | |
| Smoker, n (%) | 109.5 (56.2–170.5) | |
| Bone Erosions Non-Bone Erosions |
132.5 (48.0–346.2) 84.5 (18.0–144.2) |
0.409 |
| High ACPA (≥340) Low ACPA (<340) |
154.0 (60.0–626.0) 55.0 (8.5–132.2) |
0.024 |
| High RF (≥60) Low RF (<60) |
114.0 (38.0–267.7) 84.5 (36.0–261.7) |
0.850 |
| Double Seropositivity (RF+ ACPA+) | 61.0 (28.5–202.0) | 0.639 |
| High DAS28 (≥3.2) Low DAS28 (<3.2) |
114.0 (34.5–355.2) 86.0(43.5–225.2) |
0.470 |
| sDMARDs Non-sDMARDs |
232.5 (60.0–900.0) 111.0 (31.5–206.7) |
0.313 |
| Methotrexate Non-Methotrexate |
118.0 (36.0–206.7) 61.5 (39.0–373.7) |
0.689 |
| bDMARDs Non-bDMARDs |
175.0 (60.0–930.5) 58.5 (31.5–161.5) |
0.018 |
ACPA Anti-cyclic citrullinated peptide antibody; Disease Activity Score-28 with Erythrocyte Sedimentation Rate (DAS28-ESR); bDMARDs Biologic disease-modifying anti-rheumatic drugs; sDMARDs Synthetic disease-modifying anti-rheumatic drugs; OTUs Operational taxonomic units; RF Rheumatoid factor. Significant differences p < 0.05.